

Twinlist: Novel User Interface Designs for Medication Reconciliation

Catherine Plaisant, PhD¹, Tiffany Chao¹, Johnny Wu¹, A. Zach Hettinger, MD², Jorge Herskovic MD, PhD^{3,4}, Todd Johnson, PhD³, Elmer Bernstam, MD, MSE³, Eliz Markowitz³, Seth Powsner, MD⁵, Ben Shneiderman, PhD¹

¹University of Maryland, College Park, MD; ²Medstar Institute for Innovation, Washington DC; ³The University of Texas Health Science Center at Houston, Houston TX; ⁴MD Anderson Cancer Center, Houston, TX; ⁵Yale University, New Haven, CT

Abstract

Medication reconciliation is an important and complex task for which careful user interface design has the potential to help reduce errors and improve quality of care. In this paper we focus on the hospital discharge scenario and first describe a novel interface called Twinlist. Twinlist illustrates the novel use of spatial layout combined with multi-step animation, to help medical providers see what is different and what is similar between the lists (e.g. intake list and hospital list), and rapidly choose the drugs they want to include in the reconciled list. We then describe a series of variant designs and discuss their comparative advantages and disadvantages. Finally we report on a pilot study that suggests that animation might help users learn new spatial layouts such as the one used in Twinlist.

Introduction

Medication reconciliation is an important and complex task^{1,2,3} for which careful user interface design has the potential to reduce errors and improve quality of care. The entire process of medication reconciliation is a collaborative process in which many things can go wrong: the patients may not recall what medications they are taking (or unable to communicate); the information may not be recorded properly and include a lot of unreported uncertainty (e.g. about dosage, name or indication); the record of past medication orders may be incomplete or inaccessible; not all sources of medication orders for the patient may be known (e.g. they may have consulted a specialist on their own), etc. Eventually the clinician is presented with lists of medications from different sources that need to be reconciled into a single complete and accurate list that will be signed and saved in the patient’s medical record. Our focus has been on the last step of the process: facilitating the task of reviewing and sorting the medications that need to be continued from those that need to be stopped, following a careful and often iterative decision making process. We focused on designing the user interface to provide cognitive support that improves the speed and accuracy of medication reconciliation. We will use a single clinical scenario in our examples: discharging a patient from the hospital (Figure 1). This involves comparing the two lists, determining what drugs are unique, identical or similar between the two lists, and making medical decisions about which ones to keep, which ones to discontinue, and which to add or modify.

Intake:				Hospital:			
Acetaminophen	PO	q6h	325mg	Acetaminophen	PO	q4h	325mg
Darbepoetin	SC	qFriday	60mg	Darbepoetin	SC	qFriday	60mg
Calcitrol	PO	daily	0.25mg	Folic Acid	PO	daily	1mg
Ramipril	PO	daily	5mg	Omeprazole	PO	daily	40mg
Meloxicam	PO	daily	7.7mg	Ciproflocacin	PO	daily	500mg
Folvite	PO	daily	1mg	Ramipril	PO	daily	5mg
				Calcitrol	PO	daily	0.25mg
				Ferrous Glconate	PO	TID	300mg

Figure 1. Discharging a patient from the hospital requires providers to compare the “intake list” (left) and the “hospital list” (right) and determining what drugs are identical? unique? similar?

In this paper we describe Twinlist (Figure 2), an interface that uses spatial layout and multi-step animation to help providers better understand the similarity of the drugs included in the lists and rapidly choose the drugs to include in the reconciled list. We describe a series of variant designs, and discuss their comparative advantages and disadvantages. Finally we report on a pilot study that suggests that animation can help users learn new spatial layouts.




Figure 2. Twinlist moves identical drugs to the middle column. Drugs unique to the intake list move to the left, drugs unique to the hospital list move to the right, and drugs that are similar are aligned below, with differences highlighted in yellow (e.g. q6h versus q4h for the acetaminophen). A click on Folvite (a trade name for Folic Acid) selected it – shown as green – and deselected the Folic acid (gray and stroked). The cursor is hovering on Omeprazole, revealing all details at the bottom of the screen.

Background and Related work

There has been much research highlighting the need for improved medication reconciliation^{2, 4-9}. Duplicate/similar medications may result in overdoses and interactions as well as non-continuation of important medications. These and other hazards are further complicated by patient misunderstanding or mistrust of new medications, lack of outpatient follow-up, changes in medications due to formularies and drug shortages among others. Trial implementations of medication reconciliation policies show significant improvements. In one study, 94% of patients had some medication errors, of which a medication reconciliation process eliminated nearly all³. There are three kinds of medication error outcomes: harmful (preventable adverse drug events, or PADEs), potentially harmful (near-misses, either intercepted or avoided by sheer luck), and harmless (the most common)⁸. Unfortunately, at least 1.5 million harmful errors occurs every year⁹. Patients are particularly vulnerable to errors at care transitions^{10,11}, where medication regimens frequently change. Properly reconciling medications at these points is crucial, but complete and accurate reconciliation is difficult, and thus often overlooked or simply not performed¹², although this is changing rapidly to satisfy regulations now in place.

While many papers report and describe the severity of the problem, very few papers describe the user interfaces used in clinical settings. An exception is the Pre-Admission Medication List (PAML) Builder¹. This interface, like contemporary reconciliation interfaces, presents all medications from all sources in one combined “superlist”, grouped alphabetically by generic name. Like many contemporary reconciliation interfaces, it exhibits a visual homogeneity that does little to help clinicians identify where similar and unique medications are. Furthermore, it is difficult to survey the interfaces of currently available commercial systems due to industry concerns around intellectual property. We found that in the least usable cases clinicians might see an intake list in one window, the hospital medication list in a second window and the final discharge list in yet another window. Some systems present a single merged list listing all drugs (similar to [Poon 2006]), which at least brings close together the drugs with the same name and facilitates some level of comparisons based on drug names. Some algorithms have been proposed to automatically detect similarity between medications^{13, 14}, in a research review, described different levels of drug equivalence and showed that revealing equivalent drugs can simplify reconciliation based on a detailed keystroke analysis. Recent research tries to augment the medication lists by linking prescribed medications with clinical problems or indications, either automatically¹⁵, or using crowdsourcing¹⁶, with some limited but promising success. The literature does not yet appear to include any description of reconciliation user interfaces using that information.

Overview of Twinlist User Interface


Twinlist’s user interface consists of three parts (Figure 2): the header (top), the list viewer (center), and the item detail (bottom). The list viewer is where users may interactively accept/keep or reject/discontinue medications. An early prototype¹⁷ led to a complete rewrite using JavaScript and HTML5. See www.cs.umd.edu/hcil/sharpc for videos.

Preprocessing: A preprocessing phase is needed to identify similar drugs found in the two lists. This preprocessing phase can be accomplished using our algorithm (see Bozzo Silva et al., 2011), available at <https://github.com/jherskovic/MedRec> to find form equivalence (e.g. Tylenol is a brand name for the generic medication acetaminophen or paracetamol), or functional equivalence (Atenolol and propranolol are both betablockers). The interface then uses three categories: drugs are considered “identical” when the same drug appears on both lists (with matching name, dosage, route and form), “unique” when they appear in one list only, and “similar” when the drugs are equivalent in form but vary in dosage or other attributes, e.g. acetaminophen 650mg versus Tylenol 325mg. The class information is displayed, and can be used to group drugs as well (see later section of the paper).


Spatial groupings: Twinlist places drugs on the screen using a multi-column spatial layout (see Figure 2, and a more complex example in Figure 4 and 5). We believe that spatial groupings help Twinlist provide an intuitive way for users to quickly differentiate items that are the same from those that differ (and highlight those differences) between the two lists. The left half of the screen is for the drugs of the intake list, and the right half is for the drugs taken at the hospital. In the center column we place the identical drugs (i.e. those present in both lists: Darbepoetin, Calcitrol and Ramipril). On the far left are listed the drugs unique to intake (here only Meloxicam), on the far right the drugs unique to the hospital. Below this set of three lists we place the drugs that are similar, aligned to facilitate comparison. For example acetaminophen is present in both lists but the frequency of use is different (q6h instead of q4h) so both medications and their details are aligned in the same row, with the difference highlighted in yellow. Folvite is a brand name for folic acid so both drugs are also aligned on a common row, which helps the clinician pick which of the similar drugs is most appropriate, which may include keeping a patient on a trade name drug because they are most familiar with that name. In addition, it is important to make the source (intake vs. hospital) of each list visible so that clinicians can make reconciliation decisions from the perspective of the patient, something that was highlighted during interviews with providers.

Multi-step animation: We use a multi-step animation to help users understand the groupings of drugs (Figure 3). When the lists are loaded in Twinlist, they are first listed side by side to show the two lists: intake on the left and hospital on the right. Options are available to change the speed of the animation or turn it off, especially once a user becomes more familiar with the interface. The animation steps are as follows (Figure 3):


1. **Identical** drugs move to the center column, in-between the original lists, and then merge, one pair at a time;
2. **Unique** drugs move away from the center to their respective side, first to the left for the drugs unique to the intake list, then to the right for the drugs unique to the hospital;
3. **Similar** drugs are aligned and golden-yellow highlights are added to indicate the differences between similar drugs;
4. **Compaction** of the display is performed to save vertical space by stacking identical and unique drugs at the top of their respective columns and sliding the rows of identical drugs together below.




Start: Original layout: two separate lists




Step 1: **Identical** drugs move to the middle, one at a time.



Step 2: **Unique** drugs move to the left, then the right



Step 3: **Similar** drugs are aligned and differences highlighted



Step 4: **Compaction** of display.



Select drugs to be kept (green) or not (grayed and stroked out)

Figure 3. The 5 steps of the animation sequence used to explain the spatial groupings
See the VIDEO demonstration at www.cs.umd.edu/hcil/sharp OR search YouTube for “Twinlist demo”

Drug Selection: Through the use of spatial groupings and highlighted drug differences medical providers can rapidly make decisions to keep or discontinue drugs, one at a time or for entire columns at a time. A left-click accepts the drug, a right-click rejects it. When a drug is selected it appears green, e.g. Folvite was selected (Figure 1 or 3). Rejected drugs appear grayed out and with a strike thru the label e.g. Folic acid. Further clicking on a medication toggles through three states: accepted, rejected and undecided. Therefore making it easy to select the state with one click (left t or right click, with a two click maximum when users are not aware of the right click to reject feature). When two drugs are similar (e.g. Folvite and folic acid) the initial selection of one of the drugs automatically deselects the other, speeding up the selection process (but it is still possible to reject both drugs if needed with subsequent clicks.) The detail panel at the bottom of the screen is helpful to get more information about the drug if needed and is available with mouse-over or drug selection. When a drug has a similar drug (i.e. trade name vs. generic, different dose/route/frequency) in the other list, then all similar drugs are also highlighted in dark gray to attract the user’s attention to that similarity. Since users always hover over the drug before selecting it, they are always made aware of the similarities (Figure 4). Explicit keep and reject buttons beneath column headers provide a convenient way to accept or reject entire columns when appropriate. We chose to err on the side of caution and only apply the command to the medications that remained “undecided”, to avoid overwriting previous decisions

Signing-off: Providers click on the Sign-off button at the bottom right of the screen when the reconciliation process is done. We chose to keep the sign-off button grayed out until every medication has been reviewed and acted upon (Figure 4 and 5) to reduce the chances of medication errors. The grayed out button indicates how many drugs are still “undecided”. The sign off button includes the name of the patient, which may reduce the chance of wrong patient errors.

Figure 4. An complex example of congestive heart failure, with 11 drugs in the intake list and 12 in the hospital list. Here the cursor is on Hyzaar, so the details for that drug appear in the detail panel at the bottom (including drug class information), and the (similar) Losartan is aligned and also highlighted simultaneously. The dosage and frequency differences are highlighted in yellow.

Intake unique	Intake similar	Identical	Hospital similar	Hospital unique	
<small>keep rest reject rest [clear]</small>	<small>keep rest reject rest [clear]</small>	<small>keep rest reject rest [clear]</small>	<small>keep rest reject rest [clear]</small>	<small>keep rest reject rest [clear]</small>	
Ambien 10 mg PO qHS pm		aspirin 81 mg PO daily		furosemide 40 mg PO BID	add
Colace 100 mg PO BID		Coreg 6.25 mg PO BID		lorazepam 1-mg PO qHS-pm-ins...	edit
	acetaminophen 650 mg PO q4h pm		acetaminophen 650-mg PO q4h-pm-h...		
	Aldactone 100 mg PO daily		spironolactone 100-mg PO qAM		
	Amaryl 4 mg PO daily		glimepiride 4-mg PO qAM		
	Aricept 10 mg PO daily		donepezil 10-mg PO qAM		
	cimetidine 800 mg PO BID		cimetidine 800-mg PO q12h		
	Crestor 20 mg PO daily		rosuvastatin 20-mg PO qAM		
	Hyzaar 100 / 25 mg PO daily		losartan 50-mg PO qAM		sign off Jones

Figure 5. All drugs have been acted upon (bright green for “kept” or gray and striked for “rejected”). The Signoff button at the bottom right is now active.

Visual design

Line, color, texture, form, and space can make displays appear simple and understandable, or overly complex. In Twinlist particular attention was paid to visual design. Solid colors, used sparingly, define the interface: dark gray anchors the header to the top of the page (see Figure 4 for uncropped view of the interface); bright white creates spaciousness. Highlights provides richness: golden-yellow highlights important differences between related items; vibrant yellow-green lets users know which drugs have been selected at a glance and allows the quick review of the final set. All click-able objects further provide feedback on mouse-over: the list viewer uses a slight “nudge to the right” effect to group related medications, exploiting the immediacy of motion and the Gestalt principle of common fate to guide visual exploration. Of course color schemes and interaction cues need to be consistent with those used in the “outer” application in which the reconciliation interface is imbedded. While animation seems to be helpful in explaining the grouping and layout of the drugs, it cannot to be used in isolation. The use of unifying background colors for different groups and of course informative labels complement and support the animation.

Dealing with complex cases with further grouping

Interviews with clinicians, pharmacists and quality assurance officers indicate that medication reconciliation errors - or less than optimal choices - are more likely to occur when clinicians are dealing with difficult cases and long medication lists (see Figure 4 for a case of congestive heart failure). Twinlist’s approach readily reveals the numerous cases of similarities and differences in name, dosage or frequency, and the final reconciled set of drugs is also very clear thanks to the bold green coloring (Figure 5).

Those interviews also suggest that different types of groupings (e.g., associated problem, clinical condition, diagnosis, drug class etc.) would provide additional cognitive support for the medication reconciliation process. The current prototype allows medications to be tagged with such attributes. Those attributes can then be used to group the drugs on the display. In an ideal setting, individual medications would be linked to the patient’s problem list (demonstrating therapeutic intent), however many EHRs do not provide the ability to link the diagnosis to medication, or the function is not reliably used, limiting its current utility in the reconciliation process. There are several ongoing efforts to automatically provide linking information between drugs and the therapeutic intent in order to provide greater cognitive support to the clinician^{15, 16}. If available, this information could be shown in the detail panel, along with other medication details but it can also be used to further organize the drugs. Twinlist currently uses high level drug classifications to help users identify potential problems created by the patient’s transition from one healthcare environment to another. Using clinical condition may be even more useful. Figure 6

shows an example of grouping by primary drug class. The grouping reveals that this complex case includes a large number of anti-hypertensive medications, some of them less commonly used than others and therefore at higher risk for being misidentified.

Unfortunately, only using the primary class may not be appropriate or sufficient because medications may be prescribed for other indications or even off-label reasons (acceptable but not FDA recognized indications). This was a highly debated topic in our interviews, so we explored how the interface could show multiple (N) class affiliations. One method is to duplicate the drug N times on the screen; one for every class the drug belongs to. To indicate that the additional drug labels are merely ghost copies (and not duplicate prescriptions) they are displayed in pale gray instead of black (see Figure 7). While this grouped-by-N-class display becomes more complex (more items on the screen, resulting in longer lists), some physicians reviewing this display have commented that the visual complexity represents the complex reality of the case. During clinical use this option may be more useful in the following scenarios, but not used as a default display option: 1) during training; 2) to review decisions before sign-off in complex cases, and 3) for a subset of users that might prefer to see the drugs listed that way. Although an imperfect solution, grouping may still be more useful than the alphabetical order that is the de-facto grouping in most interfaces today.

Alternative design: Using only 2 columns and showing similarity by dynamic highlighting only

While we feel that the grouping by class is potentially useful, we also realize that the five columns of Twinlist's creates layouts where drugs become spread thinly over the entire screen, i.e. the layout loses a lot of its original compactness (e.g. comparing Figures 6 and 7 with Figure 4). This sparseness results from actually using two spatial grouping methods: grouping based on the comparison between the lists (i.e. identical, unique and similar, resulting in 5 columns) and then slicing by class, resulting in many small sets of drugs spread over the display. This led us to reconsider the original grouping in 5 columns. Our next alternative interface only uses 2 columns. We preserve the strong horizontal separation between intake (left) and hospital (right) but reserve the main vertical grouping for drug classes. The disadvantage is that similarity and differences between the lists is not shown spatially any more, but is instead revealed temporarily via highlighting when the cursor hovers over a drug (Figure 8). The only advantage is that the layout is more compact than the 5 columns with class grouping (it uses about the same screen space as the basic 5 column layout, but with a skinnier aspect ratio). A possible other advantage of this design is that it can be extended to 3 or more lists that can be shown side by side. This might be useful when reconciliation needs to merge data coming from multiple sources at once (e.g. inpatient, outpatient and a pharmacy generated list). In comparison, with the 5-column design, our design would have to repeat the 2-list reconciliation multiple times.

Intake unique	Intake similar	Identical	Hospital similar	Hospital unique
analgesic keep rest reject rest clear	acetaminophen 650 mg PO q4h pm		acetaminophen 650 mg PO q4h pm ...	
antidiabetic	Amaryl 4 mg PO daily		glimepiride 4 mg PO qAM	
sedative Ambien 10 mg PO qHS pm				lorazepam 1 mg PO qHS pm ins...
diuretic				furosemide 40 mg PO BID
antihypertensive	Aldactone 100 mg PO daily	Coreg 6.25 mg PO BID	spironolactone 100 mg PO qAM	
non-steroidal anti-inflammatory drug	Hyzaar 100 / 25 mg PO daily	aspirin 81 mg PO daily	losartan 50 mg PO qAM	
antacid	cimetidine 800 mg PO BID		cimetidine 800 mg PO q12h	
acetylcholinesterase inhibitor	Aricept 10 mg PO daily		donepezil 10 mg PO qAM	
anticholesterol	Crestor 20 mg PO daily		rosuvastatin 20 mg PO qAM	
laxative				magnesium hydroxi... 30 ml PO daily pm c...
stool softener Colace 100 mg PO BID				

Figure 6. The same case as shown in Figure 5, but now the drugs have been grouped by (primary) drug class, revealing that this complex case includes a total of 5 different anti-hypertensive medications to sort out. Ambien and Lorazepam are also now grouped in the sedative section, even though there were originally further separated. While we use drug class here, the same interface could be used to group the drugs by the patient's diagnosis- if such link information was available.

Intake unique	Intake similar	Identical	Hospital similar	Hospital unique
antipyretic			acetaminophen 650 mg PO q4h pm ...	
	acetaminophen 650 mg PO q4h pm			
		aspirin 81 mg PO daily		
analgesic	acetaminophen 650 mg PO q4h pm		acetaminophen 650 mg PO q4h pm ...	
		aspirin 81 mg PO daily		
antidiabetic	Amaryl 4 mg PO daily		glimepiride 4 mg PO qAM	
sedating	Ambien 10 mg PO qHS pm			lorazepam 1 mg PO qHS pm ins...
diuretic				furosemide 40 mg PO BID
	Hyzaar 100 / 25 mg PO daily			
antihypertensive	Aldactone 100 mg PO daily		spironolactone 100 mg PO qAM	
		Coreg 6.25 mg PO BID		
	Hyzaar 100 / 25 mg PO daily		losartan 50 mg PO qAM	
antiplatelet		aspirin		

Figure 7. Grouped by ALL drug class. Each drug appears in each class it belongs to. The primary is shown in bold, secondary copies appear as grayer shadows.

We now see that there are six antihypertensive drugs (Furosemide appears as a ghost copy of its main listing in diuretics).

Moving the cursor on Hyzaar reveals that it is also a diuretics.

Note that the list becomes longer and may require some scrolling to see all the classes.

	Intake	Hospital
analgesic	acetaminophen 650 mg PO q4h pm	acetaminophen 650 mg PO q4h pr...
antidiabetic	Amaryl 4 mg PO daily	glimepiride 4 mg PO qAM
sedative	Ambien 10 mg PO qHS pm	lorazepam 1 mg PO qHS pm i...
diuretic		furosemide 40 mg PO BID
antihypertensive	Aldactone 100 mg PO daily	Coreg 6.25 mg PO BID
	Coreg 6.25 mg PO BID	losartan 50 mg PO qAM
	Hyzaar 100 / 25 mg PO d...	spironolactone 100 mg PO qAM
non-steroidal anti-inflammatory drug	aspirin 81 mg PO daily	aspirin 81 mg PO daily
antacid	cimetidine 800 mg PO BID	cimetidine 800 mg PO q12h
acetylcholinesterase inhibitor	Aricept 10 mg PO daily	donepezil 10 mg PO qAM
anticholesterol	Crestor 20 mg PO daily	rosuvastatin 20 mg PO qAM
laxative		magnesium hydro...
stool softener	Colace 100 mg PO BID	

	Intake	Hospital
antipyretic	acetaminophen 650 mg PO q4h pm	acetaminophen 650 mg PO q4h pr...
	aspirin 81 mg PO daily	aspirin 81 mg PO daily
analgesic	acetaminophen 650 mg PO q4h pm	acetaminophen 650 mg PO q4h pr...
	aspirin 81 mg PO daily	aspirin 81 mg PO daily
antidiabetic	Amaryl 4 mg PO daily	glimepiride 4 mg PO qAM
sedative	Ambien 10 mg PO qHS pm	lorazepam 1 mg PO qHS pm i...
diuretic	Hyzaar 100 / 25 mg PO d...	furosemide 40 mg PO BID
antihypertensive	Aldactone 100 mg PO daily	Coreg 6.25 mg PO BID
	Coreg 6.25 mg PO BID	furosemide 40 mg PO BID
	Hyzaar 100 / 25 mg PO	losartan 50 mg PO qAM
		spironolactone 100 mg PO qAM
antiplatelet	aspirin 81 mg PO daily	aspirin 81 mg PO daily
non-steroidal anti-inflammatory drug	aspirin	aspirin

Figure 8. Two columns only (intake and hospital). Initially (left) the drugs are grouped by primary drug class, which naturally brings similar drugs close together and here showing the large group of anti-hypertensive medications. Highlighting reveals the further similarities (e.g. when user points at Hyzaar they can see the similarity with Losartan). Optionally, we can show all classes, with additional ghost copies when drugs belong to more than one class. Scrolling may become more likely.

Alternative design: Single column merged list

For reference we also contrast the Twinlist interface designs with an earlier design¹⁴. In Figure 9 the (now different) drugs are shown in two stacked lists: the original un-reconciled list at the top, and the reconciled list below. The identical drugs (with white background) are moved to the reconciled list automatically. In the un-reconciled list the remaining drugs are listed according to their similarity status, and color coded accordingly. Unique drugs are dark orange. Similar drugs are grouped and pale orange, and drugs of form equivalence (brand vs. generic) are grouped with a white background. In such groups, whenever two drugs have the same dosage or other attribute the cells of the table are merged elements that are the same (e.g. 25mg dosage for Coreg and the similar Pantoprazole) are merged. Drugs that are unique are given a bright orange color. The main disadvantage is that it is harder to tell to which list the drug belongs. Here the origin of the list is not used to separate the drugs spatially; instead a dedicated column provides that information. All the information about the drug is always visible in a large row.

After reviewing the list users make decisions about what to continue or discontinue. To keep one of the drugs from the top un-reconciled list to the reconciled one, users drag the corresponding row down to the bottom list. They can change their mind and slide the row back to the original list. We found that this method was effective on touchscreen devices (e.g. tablets), as dragging is easier to perform on a touch surface than with a mouse, and touchscreen users are used to dragging gestures. Dragging with a mouse between the lists is much slower and error prone, and becomes more challenging when dealing with complex cases with long lists, as the distance from the top row to the bottom list increases (on the other hand the overall display is more compact as there is no space in the vertical separation between the two original lists). Merging more than two lists is also possible, but it is not clear how to deal with multiple levels of similarity. For example a drug may be similar to another one as brand name of a generic, but may be similar to another drug of the same class. Simply grouping all drugs together loses the details of what the connections between the drugs are. Further grouping by class or indication also becomes difficult as groupings have to be repeated in both lists.

List 1 comes from		List 2 comes from	
Patient		EHR	
Unreconciled Record			
[DRAG] Patient	Protonix		
[DRAG] Ehr	Pantoprazole sodium	40 MG Take 1 tablet daily; rx	Tablet delayed release ingredients list
[DRAG] Patient	Coreg	25 MG	Tablet brand name
[DRAG] Ehr	Carvedilol	100 MCG	Tablet Unique
[DRAG] Ehr	Synthroid		
Reconciled Record			
[DRAG] Patient	Warfarin sodium	2.5 MG	Tablet
[DRAG] Patient	Lipitor	10 MG	Tablet
[DRAG] Patient	Warfarin sodium	5 MG	Tablet
[DRAG] Patient	Mirapex	0.5 MG	Tablet
[DRAG] Patient	Zoloft	50 MG	Tablet
[DRAG] Patient	Lisinopril	5 MG	Tablet

Figure 9: Alternate design: 2 stacked lists, un-reconciled at the top, and reconciled at the bottom. Drugs are grouped together by similarity. Color indicates the type of similarity. Dragging drugs from one list to the other indicates which drugs are to be kept. See video available at <http://youtu.be/hXsEQdw4LKc>

Additional design considerations

When to use animation?: While animation has been shown to be compelling and helpful to reveal transformations of complex graphical representations such as trees or graphs, other studies have also cast doubts on animation's usefulness for learning¹⁷. To look at the specific benefit of animation in Twinlist a pilot user study was conducted with 20 participants comparing Twinlist with multistep animation versus a direct jump to the final layout¹⁸. The study found no significant difference in training times when comparing the two animations, but differences were observed in terms of comments and clarification questions. For example, only 3 of the 10 participants who learned with the multi-step animation reported being initially confused about the five-column layout, compared to 9 of 10 for those who learned without animation. Fourteen out of 20 stated that they favored learning with the animation, citing its ability to “show you where everything goes” and how everything “connects”. A paired t-test for the related questionnaire item indeed indicated that the full animation was considered more helpful for learning ($p = 0.02$). The

full animation was preferred for initial learning in 70% (n=20) of participants and 90% stated they would prefer to go directly to the final layout for regular use (i.e. after learning).

The danger of scrolling: In all designs, long lists may spill over the one-screen barrier and require scrolling. The main danger of scrolling is that providers may forget to take action on some of the drugs, which led to our decision to keep the sign-off button inactive until a decision has been made for all drugs. Another effect is that some information might be out of sight when highlighting multiple drugs at once is needed. In such cases we add a special popup at the edge of the screen. In Figure 10 a “More (1)” is added at the bottom to draw users’ attention to the fact that there is more information that will require scrolling. An alternative would be temporarily animate/move the related information closer to the cursor.




Figure 10. A box labeled “More (1)” bounces up from the bottom right when there is more information requiring scrolling. Here signaling that the drug magnesium hydroxide also appears in a different class below. The subtle use of animation draws users attention.

Options and user control: The decision to group drugs by class or diagnoses, or the decision to use animation or not can be left to the end-user by providing easily accessible controls. For example in Twinlist a single click on the top menu is needed to switch between grouping by class or not, allowing rapid switching between the two views. Keyboard shortcuts are also available (C for grouping by class Class, M for multi-class, N for None). Similarly animation could be turned on and off. The naming of drugs can be changed from “as prescribed” to Brand name or generic. Further testing - along with user preference and task - should decide what option is best by default, or even what options to offer. For example the prototype also allows users to remove/hide the medication from the list once a decision has been made. It makes progress visible as users can see the list shrinks rapidly, and also decreases the need for scrolling which is important with long lists and small screens, but users also need to be able to review their decisions or change their mind so it should be made easy to toggle this hide/show option easily and not turned on by default. Those decisions should also take into consideration the interaction style used in the overall interface of the entire EHR system.

Revealing similarities within the lists: While the main role of the preprocessing and spatial layout is to clearly indicate the similarity between lists, Twinlist can also show similarity within each list. If a drug has been prescribed twice by error then the similar drugs within the list are also highlighted in dark grey on mouse-over.

Automatic reconciliation – or not? One design question is whether or not it is a good idea to automatically reconcile some of the drugs in order to speed up the process. For example designers could choose to automatically reconcile 1) all identical drugs, or 2) all unique intake drugs or 3) all intake drugs. All scenarios provide some modest gains in improving efficiency, but still require the review of the prescribing clinician and increase the likelihood of a patient being accidentally placed on a medication that should be held due to changes in their clinical condition. Twinlist’s design assumes that users review lists by moving their cursor along the list, and that selecting or deselecting drugs is easy and quick to do, more easily than having to review and then possibly cancel automatic taken actions.

Conclusion

Based on the original Twinlist design we have described a family of designs ideas that may inspire developers of Electronic Health Systems. We have received positive feedback from numerous clinicians. Comments suggest that the animation is helpful, and that the groupings are meaningful. This led to a quick pilot implementation in Microsoft Amalga, an adaptation the problem list reconciliation problem at Massachusetts General Hospital , and several ongoing projects to add Twinlist to existing EHR systems. A study looking at possible improvements in term of speed and number of less than optimal choices between the basic Twinlist interface and a baseline is planned.

Still many other designs are still possible. For example Jeffrey Belden in his HIMSS 2013 talk suggested using a separate column for the grouping by diagnoses, and then using highlighting to reveal the linkages between drugs and diagnoses. Yet another option would be to reconcile drugs one group at a time, for example by drug class, starting with the large classes (e.g. all the antihypertensive medications in our earlier example. Faced with so many options, developers have to choose a design that matches the overall design philosophy of their EHR user interface. We hope that further research will quantify the benefits of individual components of the designs (animation, groupings, etc.) and guide the development of other interfaces. Such studies will help designers make better decisions to enable

healthcare workers to accomplish their task more efficiently and safer. Finally, our work demonstrates the importance and complexity of designing health IT user interfaces that seek to provide cognitive support that improves clinician performance in terms of both speed and accuracy. To gain the full benefits of health IT, such work must be extended and repeated for all clinical tasks that an EHR must support.

Acknowledgments

This work is supported in part by Grant No. 10510592 for Patient-Centered Cognitive Support under the Strategic Health IT Advanced Research Projects Program (SHARP) from the Office of the National Coordinator for Health Information Technology. In addition we want to thank the entire SHARP-C project team for their feedback and suggestions.

References

1. Poon, E.G., Blumenfeld, B., Hamann, C., Design and implementation of an application and associated services to support interdisciplinary medication reconciliation efforts at an integrated healthcare delivery network,” *Journal of the American Medical Informatics Association*, vol. 13, no.6, 581–592, 2006
2. Poon EG. Medication reconciliation: whose job is it? *AORN J*. 2009 Jun;89(6):1180, 1122.
3. P. Pronovost, Medication reconciliation: a practical tool to reduce the risk of medication errors,” *Journal of Critical Care*, vol. 18, no. 4, pp. 201-205, Dec. 2003.
4. JCAHO: Joint commission on accreditation of healthcare organizations: Using medication reconciliation to prevent errors. Sentinel Event Alert, pages 1–4, January 2006
5. Roughead EE, Semple SJ. Medication safety in acute care in Australia: where are we now? Part 1: a review of the extend and causes of medication problems. *Aust New Zealand Health Policy*. 2009;6:18.
6. De Koning JS, Klazinga NS, Koudstaal PJ, Prins A, Dippel DW, Heerings J, et al. Quality of care in stroke prevention: results of an audit study among general practitioners. *Prev Med*. 2004;38:129-36.
7. Ellitt GR, Engblom E, Aslani P, Westerlund T, Chen TF. Drug related problems after discharge from a Australian teaching hospital. *Pharm World Sci*. 2010.
8. C. A. Keohane and D. W. Bates, “Medication safety,” *Obstetrics and Gynecology Clinics of North America*, vol. 35, no. 1, pp. 37-52, viii, Mar. 2008.
9. CIPME: Committee on Identifying and Preventing Medication Errors (CIPME), *Preventing medication errors*. Washington, DC: National Academies Press, 2007.
10. J. Rozich and R. Resar, “Medication safety: one organization’s approach to the challenge,” *Journal of Clinical Outcomes Management*, vol. 8, no. 10, pp. 27–34, 2001.
11. A. J. Forster, H. J. Murff, J. F. Peterson, T. K. Gandhi, and D. W. Bates, “The incidence and severity of adverse events affecting patients after discharge from the hospital,” *Annals of Internal Medicine*, vol. 138, no. 3, pp. 161-7, Feb. 2003.
12. G. Rogers et al., “Reconciling medications at admission: safe practice recommendations and implementation strategies,” *Joint Commission Journal on Quality and Patient Safety Joint Commission Resources*, vol. 32, no. 1, pp. 37-50, Jan. 2006.
13. Bozzo Silva, Bernstam, Markowitz, Johnson, Zhang and Herskovic, Automated medication reconciliation and complexity of care transitions, *Proc. AMIA 2011*, 1252–1260.
14. Markowitz, E., Bernstam, E., Herskovic, J., Zhang, J., Shneiderman, B., Plaisant, C., Johnson, T., Medication Reconciliation: Work Domain Ontology, Prototype Development, and a Predictive Model, *AMIA Annual Symp Proc*. (2011) 878-87
15. Burton, M, Simonaitis, L. and Schadow, G., Medication and Indication Linkage: A Practical Therapy for the Problem List? *AMIA Annual Symp Proc*. (2008) 86–90.
16. McCoy AB, Wright A, Laxmisan A, Ottosen MJ, McCoy JA, Batten D, Sittig DF. , Development and evaluation of a crowdsourcing methodology for knowledge base construction: identifying relationships between clinical problems and medications. *J Am Med Inform Assoc*. 19(5) (2012) 713-8.
17. Claudino, L., Khamis, S., Liu, R., London, B., Pujara, J., Plaisant, C., Shneiderman, B., Facilitating Medication Reconciliation with Animation and Spatial layout, *Proc. Workshop on Interactive Healthcare Systems (WISH2011)* --- Copyright retained by authors ---.
18. Tversky, B. Visualizing thought. *Topics in Cognitive Science*, 3, 3 (2011) 499–535
19. Plaisant, C., Chao, T., Liu, R., Norman, K., Shneiderman, B. , Multi-Step Animation to Facilitate the Understanding of Spatial Groupings: the Case of List Comparisons, *University of Maryland Technical Report HCIL-2012-23* (2012)